BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33112842)

  • 21. Identification of Novel Mutations and Expressions of
    Islam F; Pillai S; Gopalan V; Lam AK
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Therapies in Pheochromocytoma and Paraganglioma.
    Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
    Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
    Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?
    Papathomas TG; Suurd DPD; Pacak K; Tischler AS; Vriens MR; Lam AK; de Krijger RR
    Endocr Pathol; 2021 Mar; 32(1):134-153. PubMed ID: 33433885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Metastatic risk factors in pheochromocytoma/paraganglioma].
    Rebrova DV; Loginova OI; Vorobyev SL; Vorokhobina NV; Kozorezova ES; Indeykin FA; Savelyeva TV; Sleptsov IV; Chernikov RA; Fedorov EA; Semenov AA; Chinchuk IK; Shikhmagomedov SS; Alekseev MA; Krasnov LM; Rusakov VF
    Probl Endokrinol (Mosk); 2023 Oct; 70(2):37-45. PubMed ID: 38796759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
    Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
    Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
    Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
    Jochmanová I; Yang C; Zhuang Z; Pacak K
    J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas.
    Jones RB; Cohen DL
    Curr Cardiol Rep; 2023 Nov; 25(11):1451-1460. PubMed ID: 37847359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
    Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
    Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deciphering the molecular basis of invasiveness in Sdhb-deficient cells.
    Loriot C; Domingues M; Berger A; Menara M; Ruel M; Morin A; Castro-Vega LJ; Letouzé É; Martinelli C; Bemelmans AP; Larue L; Gimenez-Roqueplo AP; Favier J
    Oncotarget; 2015 Oct; 6(32):32955-65. PubMed ID: 26460615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Landscape of Pheochromocytoma and Paraganglioma.
    Jochmanova I; Pacak K
    Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.
    Richter S; Qin N; Pacak K; Eisenhofer G
    Adv Pharmacol; 2013; 68():285-317. PubMed ID: 24054150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.